Payment overview · 2025
General Payments
$736.76
10 reported records · 5 companies
Healthcare provider profile · identity verified
Andrew C. Seipel, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEWARK, OH · NPI 1578530127
Verified facts
What the public records show
CMS Open Payments records show Andrew C. Seipel, MD received $736.76 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $249.46 | 33.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $232.65 | 31.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $199.75 | 27.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.37 | 5.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.53 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $736.76 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $241.62 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $241.62 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $232.65 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $199.75 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.37 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $7.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 602 | 189 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 105 |
| Lisinopril | Lisinopril | 289 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 79 |
| Omeprazole | Omeprazole | 230 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 180 | 58 |
| Metformin Hcl | Metformin Hcl | 179 | 64 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 161 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 50 |
| Gabapentin | Gabapentin | 155 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 42 |
| Losartan Potassium | Losartan Potassium | 145 | 48 |
| Tramadol Hcl | Tramadol Hcl | 137 | 38 |
| Simvastatin | Simvastatin | 134 | 41 |
| Eliquis | Apixaban | 128 | 29 |
| Metformin Hcl Er | Metformin Hcl | 111 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 36 |
| Ozempic | Semaglutide | 109 | 29 |
| Benazepril Hcl | Benazepril Hcl | 108 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 32 |
| Jardiance | Empagliflozin | 104 | 32 |
| Carvedilol | Carvedilol | 98 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 28 |
| Sertraline Hcl | Sertraline Hcl | 93 | 34 |
| Alendronate Sodium | Alendronate Sodium | 91 | 31 |
| Alprazolam | Alprazolam | 88 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 88 | 28 |
| Furosemide | Furosemide | 87 | 30 |
| Glimepiride | Glimepiride | 73 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 26 |
| Finasteride | Finasteride | 72 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 25 |
| Valsartan | Valsartan | 67 | 25 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 61 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | suppressed |
| Ezetimibe | Ezetimibe | 55 | 19 |
| Spironolactone | Spironolactone | 54 | 19 |
| Famotidine | Famotidine | 53 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 14 |
| Allopurinol | Allopurinol | 51 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 20 |
| Potassium Chloride | Potassium Chloride | 49 | 19 |
| Trazodone Hcl | Trazodone Hcl | 49 | 14 |
| Warfarin Sodium | Warfarin Sodium | 48 | 18 |
| Bupropion Xl | Bupropion Hcl | 46 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 12 |
| Buspirone Hcl | Buspirone Hcl | 44 | 15 |
| Meloxicam | Meloxicam | 44 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 18 |
| Januvia | Sitagliptin Phosphate | 42 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | 12 |
| Farxiga | Dapagliflozin Propanediol | 35 | 14 |
| Montelukast Sodium | Montelukast Sodium | 35 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 11 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Prednisone | Prednisone | 18 | 15 |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Tradjenta | Linagliptin | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $736.76 · 10 records | ABBVIE INC. | Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Ozempic, QULIPTA, SHINGRIX, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error